NCT06789341 (HP-RETROSS) is a clinical trial in Gastric Cancer Patient, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT06789341?

NCT06789341 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What condition does NCT06789341 study?

NCT06789341 studies Gastric Cancer Patient.

Is NCT06789341 still recruiting?

NCT06789341 is currently completed. Last updated 23 January 2025.

Last reviewed 2025-01-23 · How we verify

NCT06789341: HP-RETROSS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Data Collection for a Correlation Study Between Gastric Cancer and Clinical and Laboratory Variables

Completed Last updated 23 January 2025

What this trial tests

trial in Gastric Cancer Patient in 130 participants. Completed in 28 December 2023.

Timeline

20 January 2022

Primary endpoint
28 December 2023

28 December 2023

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status	Completed
Study type	OBSERVATIONAL
Enrollment	130
Start date	20 January 2022
Primary completion	28 December 2023
Estimated completion	28 December 2023
Sites	1 location across Italy

Conditions studied

Gastric Cancer Patient — all drugs for Gastric Cancer Patient →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with Gastric Cancer Patient. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, retrospective, case-control, single-center, national study that involves the collection of anamnestic, clinical and therapeutic data of patients diagnosed with gastric cancer by histological examination at the Pathological Anatomy Unit (Prof. D'Errico) in the period 2016-2020.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06789341 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 23 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06789341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing